270 related articles for article (PubMed ID: 36542765)
1. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
Krajewski PK; Szepietowski JC
Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
[TBL] [Abstract][Full Text] [Related]
4. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
[TBL] [Abstract][Full Text] [Related]
5. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
[TBL] [Abstract][Full Text] [Related]
8. Review of Ruxolitinib in the Treatment of Atopic Dermatitis.
Mohney LA; Singh R; Feldman SR
Ann Pharmacother; 2023 Feb; 57(2):207-216. PubMed ID: 35674400
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
[No Abstract] [Full Text] [Related]
11. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
13. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Uppal SK; Chat VS; Kearns DG; Wu JJ
J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
[TBL] [Abstract][Full Text] [Related]
14. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
16. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
17. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
18. JAK/STAT inhibitors for the treatment of atopic dermatitis.
Rodrigues MA; Torres T
J Dermatolog Treat; 2020 Feb; 31(1):33-40. PubMed ID: 30703333
[No Abstract] [Full Text] [Related]
19. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
Blauvelt A; Kircik L; Papp KA; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Szepietowski JC
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):137-146. PubMed ID: 36066323
[TBL] [Abstract][Full Text] [Related]
20. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF
J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]